文献速递重症综合管理与镇静镇痛

重症监护病房耳念珠菌暴发及其控制

A Candida auris Outbreak and Its Control in an Intensive Care Setting.
PubMed 文献 · N Engl J Med · 2018-01-01
一句话结论神经科学ICU耳念珠菌暴发与可重复使用腋温探头及全身氟康唑暴露相关,仅移除体温探头后新发病例才减少。

该研究报道英国牛津大学医院神经科学ICU的耳念珠菌定植与感染暴发。2015年2月2日至2017年8月31日共识别70例定植或感染患者,其中66例(94%)在诊断前曾入住神经科学ICU,7例发生侵袭性感染。控制ICU住院时长及生命体征和实验室结果后,定植或感染的预测因素包括使用可重复使用皮肤表面腋温探头(多变量OR 6.80,95%CI 2.96至15.63,P<0.001)和全身氟康唑暴露(多变量OR 10.34,95%CI 1.64至65.18,P=0.01)。一般环境中罕见检出耳念珠菌,但可重复使用设备(包括多个腋温探头)分离株中检出,且与患者分离株基因相关;尽管实施感染控制集束化干预,仅在移除体温探头后新发病例发生率才下降。

要点

  • 70例耳念珠菌定植或感染中66例(94%)诊断前曾入住神经科学ICU,7例发生侵袭性感染。
  • 控制ICU住院时长及生命体征和实验室结果后,使用可重复使用皮肤表面腋温探头者定植或感染风险增高(多变量OR 6.80,95%CI 2.96至15.63,P<0.001)。
  • 控制相同因素后,全身氟康唑暴露者定植或感染风险增高(多变量OR 10.34,95%CI 1.64至65.18,P=0.01)。
  • 一般环境罕见检出耳念珠菌,但可重复使用设备(包括多个腋温探头)分离株中检出,且与患者分离株基因相关。
  • 实施感染控制集束化干预后新发病例未减少,仅在移除体温探头后新发病例发生率才下降。

适用人群与场景

  • 英国牛津大学医院神经科学ICU收治的患者,2015年2月2日至2017年8月31日期间被识别为耳念珠菌定植或感染。

处置流程与药物剂量

  • 识别神经科学ICU耳念珠菌感染聚集后,实施强化的患者与环境筛查程序及一揽子干预措施。
  • 实施感染控制集束化干预后新发病例未减少,移除可重复使用腋温探头后新发病例发生率才下降。

研究设计与关键结果

  • 研究类型为医院暴发流行病学调查,共识别70例耳念珠菌定植或感染患者,其中66例(94%)诊断前曾入住神经科学ICU,7例发生侵袭性感染。
  • 控制神经科学ICU住院时长及患者生命体征和实验室结果后,定植或感染的预测因素包括使用可重复使用皮肤表面腋温探头(多变量OR 6.80,95%CI 2.96至15.63,P<0.001)和全身氟康唑暴露(多变量OR 10.34,95%CI 1.64至65.18,P=0.01)。
  • 一般环境中罕见检出耳念珠菌,但可重复使用设备(包括多个腋温探头)分离株中检出,且测序分离株与患者分离株基因相关。
  • 所有暴发序列形成耳念珠菌南非分支内的单一基因簇。
  • 实施感染控制集束化干预后新发病例未减少,仅在移除体温探头后新发病例发生率下降。

证据类型、等级与局限

  • 证据类型为医院暴发流行病学调查,采用多变量逻辑回归和全基因组测序。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为此次医院暴发中耳念珠菌传播与可重复使用腋温探头相关,提示该新兴病原体可在环境中持续存在并在医疗环境中传播。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Candida auris is an emerging and multidrug-resistant pathogen. Here we report the epidemiology of a hospital outbreak of C. auris colonization and infection.

METHODS: After identification of a cluster of C. auris infections in the neurosciences intensive care unit (ICU) of the Oxford University Hospitals, United Kingdom, we instituted an intensive patient and environmental screening program and package of interventions. Multivariable logistic regression was used to identify predictors of C. auris colonization and infection. Isolates from patients and from the environment were analyzed by whole-genome sequencing.

RESULTS: A total of 70 patients were identified as being colonized or infected with C. auris between February 2, 2015, and August 31, 2017; of these patients, 66 (94%) had been admitted to the neurosciences ICU before diagnosis. Invasive C. auris infections developed in 7 patients. When length of stay in the neurosciences ICU and patient vital signs and laboratory results were controlled for, the predictors of C. auris colonization or infection included the use of reusable skin-surface axillary temperature probes (multivariable odds ratio, 6.80; 95% confidence interval [CI], 2.96 to 15.63; P<0.001) and systemic fluconazole exposure (multivariable odds ratio, 10.34; 95% CI, 1.64 to 65.18; P=0.01). C. auris was rarely detected in the general environment. However, it was detected in isolates from reusable equipment, including multiple axillary skin-surface temperature probes. Despite a bundle of infection-control interventions, the incidence of new cases was reduced only after removal of the temperature probes. All outbreak sequences formed a single genetic cluster within the C. auris South African clade. The sequenced isolates from reusable equipment were genetically related to isolates from the patients.

CONCLUSIONS: The transmission of C. auris in this hospital outbreak was found to be linked to reusable axillary temperature probes, indicating that this emerging pathogen can persist in the environment and be transmitted in health care settings. (Funded by the National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University and others.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Eyre DW, Sheppard AE, Madder H, et al. A Candida auris Outbreak and Its Control in an Intensive Care Setting. N Engl J Med. 2018. PMID: 30281988. doi:10.1056/NEJMoa1714373

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。